LCE1F Inhibitors
LCE1F Inhibitors are a diverse set of chemical compounds that lead to diminished functional activity of LCE1F through their influence on cellular differentiation, proliferation, and immune responses. Phorbol 12-myristate 13-acetate (PMA) and retinoic acid, for instance, exert their inhibitory effects on LCE1F by promoting the differentiation of keratinocytes, a process during which LCE1F expression is typically downregulated. Similarly, calcipotriol and calcitriol, both analogs of vitamin D, bind to the vitamin D receptor, resulting in a promotion of differentiation and an accompanying reduction in LCE1F expression. Hydroquinone and methotrexate contribute to this effect through their respective cytotoxic and antimetabolite actions, leading to changes in keratinocyte turnover and a consequent decrease in LCE1F levels. Imiquimod and Cyclosporin A, though differing in their primary functions as an immune response modifier and an immunosuppressant, respectively, both result in reduced LCE1F expression by altering immune pathways and affecting keratinocyte behavior.
The influence of other inhibitors on LCE1F is linked to their capacity to modulate keratinocyte behavior and epidermal renewal processes. Fluorouracil, tazarotene, and Anthralin, each with distinct mechanisms impacting DNA and RNA synthesis or normalizing DNA activity, ultimately lead to reduced proliferation and enhanced differentiation of keratinocytes, thereby diminishing LCE1F expression. Salicylic acid, through its keratolytic properties, accelerates the shedding of the epidermis, which can indirectly lower LCE1F levels as part of the skin's natural regulatory processes. These LCE1F inhibitors, through their targeted actions on various biochemical and cellular pathways, collectively contribute to the reduced functional activity of LCE1F without directly impacting its transcription or translation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol (DAG) analog that activates protein kinase C (PKC). PKC activation leads to altered cellular functions that can indirectly inhibit LCE1F expression by promoting differentiation pathways in keratinocytes where LCE1F expression is normally downregulated. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a metabolite of vitamin A, modulates skin cell differentiation. By promoting differentiation of keratinocytes, retinoic acid can lead to decreased expression of LCE1F, which is associated with the epidermal differentiation complex. | ||||||
Calcipotriol | 112965-21-6 | sc-203537 sc-203537A | 10 mg 50 mg | $203.00 $832.00 | 4 | |
Calcipotriol, a vitamin D analog, binds to the vitamin D receptor and influences gene expression. In keratinocytes, it promotes differentiation and suppresses proliferation, thereby potentially decreasing LCE1F expression, which is involved in the late stages of epidermal formation. | ||||||
Hydroquinone | 123-31-9 | sc-204773 sc-204773A sc-204773B | 250 g 1 kg 5 kg | $37.00 $93.00 $400.00 | ||
Hydroquinone is a skin-lightening agent that can alter melanocyte function and keratinocyte behavior. Through its cytotoxic effects on melanocytes, it may lead to an indirect reduction in LCE1F expression due to alterations in keratinocyte turnover and differentiation. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate is an antimetabolite and antifolate drug that inhibits dihydrofolate reductase, leading to decreased DNA synthesis. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod is an immune response modifier that can lead to local inflammation and altered keratinocyte differentiation. By activating immune pathways, it can indirectly result in decreased expression of LCE1F, which is part of the epidermal differentiation complex. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, thereby disrupting DNA and RNA synthesis. Its application in actinic keratosis and other skin conditions may indirectly diminish LCE1F expression due to its effects on keratinocyte proliferation and differentiation. | ||||||
Tazarotene | 118292-40-3 | sc-220193 | 10 mg | $103.00 | ||
Tazarotene is a topical retinoid that affects gene expression related to skin cell growth and differentiation. By modulating these processes, tazarotene can lead to a reduction in LCE1F expression, which is typically involved in the late stages of epidermal differentiation. | ||||||
Salicylic acid | 69-72-7 | sc-203374 sc-203374A sc-203374B | 100 g 500 g 1 kg | $47.00 $94.00 $119.00 | 3 | |
Salicylic acid has keratolytic properties and can influence epidermal turnover. By enhancing the shedding of the outer layer of the skin, salicylic acid may indirectly lead to diminished expression of LCE1F as part of the regulatory processes in skin differentiation and renewal. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that inhibits calcineurin, leading to T-cell inactivation and reduced cytokine production. In the context of skin, it may indirectly suppress LCE1F expression by modulating immune responses and influencing keratinocyte differentiation. | ||||||